BJUI Mini Reviews - Phosphodiesterase Type 5 Inhibitors in the Management of Erectile Dysfunction Secondary to Treatments for Prostate Cancer: Findings from a Cochrane Systematic Review
This article is an exploration, in systematic review, of the effectiveness, safety and potential optimal use of PDE5i for erectile dysfunction following treatments for prostate cancer.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2009 UroToday ® All Rights Reserved |
